348 related articles for article (PubMed ID: 33277879)
21. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
[TBL] [Abstract][Full Text] [Related]
22. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
24. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
[TBL] [Abstract][Full Text] [Related]
25. Results of a single-arm pilot study of
Ross PJ; Wasan HS; Croagh D; Nikfarjam M; Nguyen N; Aghmesheh M; Nagrial AM; Bartholomeusz D; Hendlisz A; Ajithkumar T; Iwuji C; Wilson NE; Turner DM; James DC; Young E; Harris MT
ESMO Open; 2022 Feb; 7(1):100356. PubMed ID: 34953400
[TBL] [Abstract][Full Text] [Related]
26. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
[TBL] [Abstract][Full Text] [Related]
28. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.
Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
Surg Oncol; 2020 Dec; 35():285-297. PubMed ID: 32949968
[TBL] [Abstract][Full Text] [Related]
30. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
31. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836
[TBL] [Abstract][Full Text] [Related]
32. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
[TBL] [Abstract][Full Text] [Related]
33. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Auclin E; Marthey L; Abdallah R; Mas L; Francois E; Saint A; Cunha AS; Vienot A; Lecomte T; Hautefeuille V; de La Fouchardière C; Sarabi M; Ksontini F; Forestier J; Coriat R; Fabiano E; Leroy F; Williet N; Bachet JB; Tougeron D; Taieb J
Br J Cancer; 2021 Jun; 124(12):1941-1948. PubMed ID: 33772154
[TBL] [Abstract][Full Text] [Related]
34. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
[TBL] [Abstract][Full Text] [Related]
35. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Ecker BL; Court CM; Janssen QP; Tao AJ; D'Angelica MI; Drebin JA; Gonen M; O'Reilly EM; Jarnagin WR; Wei AC;
J Am Coll Surg; 2022 Aug; 235(2):342-349. PubMed ID: 35839413
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Choi YJ; Byun Y; Kang JS; Kim HS; Han Y; Kim H; Kwon W; Oh DY; Paik WH; Lee SH; Ryu JK; Kim YT; Lee K; Kim H; Chie EK; Jang JY
Gut Liver; 2021 May; 15(3):466-475. PubMed ID: 32839360
[TBL] [Abstract][Full Text] [Related]
38. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
[TBL] [Abstract][Full Text] [Related]
39. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
[TBL] [Abstract][Full Text] [Related]
40. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]